1 | 0,25 mg RPC1063 | - | - | - | - | 1件: 96 96 |
2 | 0.25 mg RPC1063 | - | - | - | - | 3件: 13 13, 96, 97 |
3 | 0.25mg RPC1063 | - | - | - | - | 2件: 13 13, 97 |
4 | 0.5 mg RPC1063 | - | - | - | - | 2件: 13 13, 97 |
5 | 0.5mg RPC1063 | - | - | - | - | 1件: 13 13 |
6 | 1 mg RPC1063 | - | - | - | - | 2件: 13 13, 97 |
7 | 1.0 mg RPC1063 | - | - | - | - | 1件: 97 97 |
8 | 1.0mg RPC1063 | - | - | - | - | 1件: 13 13 |
9 | 14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration | - | - | - | - | 3件: 13 13, 96, 97 |
10 | 1mg RPC1063 | - | - | - | - | 1件: 96 96 |
11 | RPC1063 | - | - | - | - | 3件: 13 13, 96, 97 |
12 | RPC1063 (equivalent to ozanimod | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 |
13 | RPC1063 (equivalent to ozanimod HCl) | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 |
14 | RPC1063 equiv to ozanimod HCI | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 |
15 | RPC1063 equiv. to ozanimod HCI | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 |